OncoCyte : Results of Operations and Financial Condition - Form 8-K

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549



FORM 8-K



CURRENT REPORT


... | April 5, 2023

Related Keywords

United States ,Washington ,California ,Irvine ,Icis Keytruda ,Medicaid Services ,Nasdaq ,Clinical Laboratory Improvements Amendment ,Lab Developed Tests Ltds ,Like Pharma Services ,Research Use Only ,Molecular Diagnostics Services Moldx ,Oncocyte Corporation ,Razor Genomics Inc ,Nasdaqstock Market ,Securities Exchange ,Drug Administration ,Burning Rock Biotech ,Trademark Office ,Centers For Medicare ,Oncocyte Corporation The Company ,Early Access Program ,Dragon Scientific ,Nasdaq Stock Market ,Pharma Services ,Exchange Commission ,Securities Exchange Act ,Exchange Act ,Securities Act ,Current Report ,Lab Developed Tests ,Chronix Biomedical ,United States Patent ,Molecular Diagnostics Services ,Insight Genetics ,Tumor Mutational Burden ,Razor Genomics ,Nasdaq Global Market ,Nasdaq Capital ,Nasdaq Capital Market ,Stock Purchase Agreement ,Stock Purchase ,Razor Stock Purchase Agreement ,Razor Sale ,Year Ended December ,Initial Milestone Payments ,Exclusive Sublicense Agreement ,Net Revenue ,Annual Report ,Private Securities Litigation Reform Act ,Oncocyte Corporation Stock Exchange ,News ,Information ,Press Release ,United ,Securities ,End ,Exchange ,Form ,Urrent Ocx Us68235c1071 ,